697739-03-0

Basic information

• Product Name: 5-FLUORO-2-METHYL-3-NITRO-BENZOIC ACID METHYL ESTER
• Synonyms: 5-FLUORO-2-METHYL-3-NITRO-BENZOIC ACID METHYL ESTER;5-fluoro-2-methyl-3-nitrobenzoic acid;Benzoic acid, 5-fluoro-2-Methyl-3-nitro-, Methyl ester;5-fluoro-2-Methyl-3-nitro-, Methyl ester;Methyl 5-fluoro-2-Methy-3-nitrobenzoate
• CAS NO: 697739-03-0
• Molecular Formula: C₉H₈FNO₄
• Molecular Weight: 213.163
• Mol File: 697739-03-0.mol

Chemical Properties

• Boiling Point: 297.7±40.0 °C(Predicted)
• Appearance: /
• Density: 1.335±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Slightly soluble in water. Soluble in dimethyl sulfoxide and acetone.
• CAS DataBase Reference: 5-FLUORO-2-METHYL-3-NITRO-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-FLUORO-2-METHYL-3-NITRO-BENZOIC ACID METHYL ESTER(697739-03-0)
• EPA Substance Registry System: 5-FLUORO-2-METHYL-3-NITRO-BENZOIC ACID METHYL ESTER(697739-03-0)

Safety Data

• Hazardous Substances Data: 697739-03-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-FLUORO-2-METHYL-3-NITRO-BENZOIC ACID METHYL ESTER is used as an intermediate in the synthesis of various organic compounds. Its unique structural features make it a valuable building block for the development of new molecules with potential applications in different industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-FLUORO-2-METHYL-3-NITRO-BENZOIC ACID METHYL ESTER is used as a key intermediate in the synthesis of 6-Fluoro-4-nitroisobenzofuran-1 (3H)-one, which is an important compound for the development of new drugs. 5-FLUORO-2-METHYL-3-NITRO-BENZOIC ACID METHYL ESTER has potential applications in the treatment of various diseases, including cancer, due to its ability to modulate cellular signaling pathways and inhibit tumor growth.

Preparation

Methyl 5-fluoro-2-methyl-3-nitrobenzoate synthesis: To a solution of conc. H2SO4 (700mL) was added portionwise 5-fluoro-2-methylbenzoic acid (80g, 520 mmol) at -5-0°C. Then a mixture of conc. HNO3(60.4 g. 624 mmol) in conc. H2SO4 (60 mL) was added drop-wise at -5-0°C. in a period of about 1.5 hrs. After the addition, the mixture was stirred at this temperature for 2 hrs. TLC (petroleum ether/ EtOAc=1:1) showed the reaction was complete. The mixture was poured into crash ice with vigorous stirring and the precipitate was collected by filtration. The precipitate was dissolved in EtOAc, washed with brine, dried over anhydrous Na2SO4 concentrated to give crude 5-fluoro-2-methyl-3-nitrobenzoic acid (54 g). A solution of this crude 5-fluoro-2-methyl-3-nitrobenzoic acid (54 g) in dry methanol (500 mL) was cooled to 0°C., SOCl2 (64.52g, 542.3 mmol) was added drop-wise. After the addition, the mixture was heated to reflux for 16hrs. TLC (petroleum ether/EtOAc=1:1) showed the reaction was complete. Solvent was removed under reduced pressure to give crude product. The crude product was purified by silica gel chromatography (petroleum ether to petro leum ether/EtOAc=50: 1) to give methyl 5-fluoro-2-methyl-3-nitrobenzoate (28 g, yield 25% for two steps) as a white solid.

InChI:InChI=1/C9H8FNO4/c1-5-7(9(12)15-2)3-6(10)4-8(5)11(13)14/h3-4H,1-2H3

Upstream product

• 67-56-1 methanol 
• 33184-16-6 5-fluoro-2-methylbenzoic acid 
• 13194-67-7 4-fluoro-2-iodotoluene 
• 1422-53-3 2-bromo-4-fluorotoluene 
• 452-73-3 2-chloro-4-fluorotoluene 
• 175278-29-2 5-fluoro-2-methylbenzoic acid methyl ester 
• 850462-64-5 5-fluoro-2-methyl-3-nitrobenzoic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 1207453-97-1 8-(4-((dimethylamino)methyl)phenyl)-9-(1-methyl-1H-imidazol-2-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one 
• 1207455-40-0 9-(1-methyl-1H-imidazol-2-yl)-8-(4-(pyrrolidin-1-ylmethyl)phenyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one 
• 1207453-90-4 6-fluoro-4-nitroisobenzofuran-1(3H)-one 
• 1207453-91-5 4-amino-6-fluoroisobenzofuran-1(3H)-one 
• 1207453-92-6 (E)-4-(benzylideneamino)-6-fluoroisobenzofuran-1(3H)-one 
• 1207453-93-7 ethyl 7-fluoro-3-(1-methyl-1H-imidazol-2-yl)-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1207453-95-9 (E)-6-fluoro-4-(4-fluorobenzylideneamino)isobenzofuran-1(3H)-one 
• 1207453-98-2 ethyl 2-(4-(diethoxymethyl)phenyl)-3-(1-methyl-1H-imidazol-2-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1207453-99-3 8-(4-(diethoxymethyl)phenyl)-9-(1-methyl-1H-imidazol-2-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one 
• 1207454-00-9 4-(9-(1-methyl-1H-imidazol-2-yl)-3-oxo-3,7,8,9-tetrahydro-2H-pyrido[4,3,2-de]phthalazin-8-yl)benzaldehyde 
• 1207454-57-6 ethyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1207455-88-6 ethyl 7-fluoro-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1207453-96-0 methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-imidazol-2-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 283173-50-2 Rucaparib 

Relevant articles and documents

Isoindoline compound, and preparation method, pharmaceutical composition and application thereof

The invention relates to a polysubstituted isoindoline compound represented by a general formula (I), and a preparation method, a pharmaceutical composition and an application thereof. Specifically, as a CRL4CRBNE3 ubiquitin ligase regulator with a novel structure, the polysubstituted isoindoline compound provided by the invention has stronger anti-tumor activity and an anti-tumor spectrum, and can be used for preparing medicines for treating diseases related to CRL4CRBNE3 ubiquitin ligase.

ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

METHOD FOR PREPARATION OF 5-FLUORO-2-METHYL-3-NITROBENZOIC ACID AND ITS METHYL ESTER

The invention discloses a method for preparation of 5-fluoro-2-methyl-3-nitrobenzoic acid and its methyl ester by conversion of 5-fluoro-2-methylbenzoic acid with fuming nitric acid and oleum and subsequent conversion with methanol.

ETHER COMPOUNDS AND USES THEREOF

The present invention provides compounds that modulate protein function, to restore protein homeostasis and/or cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions of these compounds are also provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions are also provided.

Preparation method for 2-methyl-5-fluorobenzoic acid

The invention discloses a preparation method for 2-methyl-5-fluorobenzoic acid. The method comprises the steps of reacting 2-X-4-fluorotoluene with magnesium chips to form a Grignard reagent, and converting the obtained Grignard reagent to obtain the 2-methyl-5-fluorobenzoic acid, wherein X is selected from chloro, bromo or iodo.

Preparation method of ovarian cancer resistance medicine Rucaparib key intermediate

The invention discloses a preparation method of an ovarian cancer resistance medicine Rucaparib key intermediate, and relates to preparation of medical intermediates. A compound 1 takes methyl alcoholand cyclohexane as solvents, toluenesulfonic acid serve

Isoindoline derivative and intermediate, preparation method, pharmaceutical composition and application thereof

The invention discloses an isoindoline derivative, and an intermediate, a preparation method, a pharmaceutical composition and application thereof. The isoindoline derivative of the invention and the pharmaceutical composition thereof can adjust productio

Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation

A series of AG014699 derivatives containing a novel scaffold of 2,3-dihydro-1H-[1,2]diazepino[4,5,6-cd]indole-1,4(6H)-dione were synthesized and evaluated for their inhibitory activities toward PARP-1 enzyme and two cell lines, MCF-7 cells and the BRCA1-deficient MDA-MB-436 cells. Our results demonstrated that of all AG014699 derivatives synthesized in this work, compounds 6 and 7 showed strong PARP-1 inhibitory activity (IC50 = 3.5 nM and 2.4 nM, respectively), only four and three times less potent than AG014699. Compound 6 also had significantly cell inhibitory activity against both MCF-7 cells (CC50 = 25.8 μM) and the BRCA1-deficient MDA-MB-436 cells (CC50 = 5.4 μM), nearly as good as AG014699, indicating that it can be a promising compound for further evaluation.

Multkilogram scale-up of a reductive alkylation route to a novel PARP inhibitor

Novel PARP inhibitor 1 is a promising new candidate for treatment of breast and ovarian cancer. A modified synthetic route to 1 has been developed and demonstrated on 7 kg scale. In order to scale up the synthesis to multikilogram scale, several synthetic challenges needed to be overcome. The key issues included significant thermal hazards present in a Leimgruber-Batcho indole synthesis, a low-yielding side-chain installation, a nonrobust Suzuki coupling and hydrogen cyanide generation during a reductive amination. In addition to these issues, changing from intravenous to oral delivery required a new salt form and therefore a new crystallization procedure. This contribution describes development work to solve these issues and scaling up of the new process in the pilot plant.

METHODS OF USING DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE)POLYMERASE (PARP)

Provided herein are methods of treating cancer comprising administering a topoisomerase inhibitor, temozolomide, or a platin in combination with a Compound of Formula (I) or Formula (II), where the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein.